In the study by Klampfl et al., a multivariate analysis demonstrated that MPN patients with JAK2 and MPL mutations had a higher risk of death than ET and PMF patients with CALR mutations.7 In the study by Nangalia et al.8 no apparent survival difference was found between the two ET mutational groups. Here, JAK2 is linked to myeloproliferative neoplasm.